GlassScriptPhysician profile
Ramzi W Saad
NPI 1508862467
$5,340.76
in general payments reported to CMS, 2019-2025
22 companies · $797 in 2025
The $797 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $320 · 2020: $209 · 2021: $479 · 2022: $904 · 2023: $1,252 · 2024: $1,381 · 2025: $797.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,239 · Education: $160 · Grant: $30.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,238.89 |
| Education | $159.98 |
| Grant | $30.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,326.84 | 2019-2025 | Skyrizi, Rinvoq |
| Genzyme Corporation | $828.06 | 2021-2025 | |
| Janssen Biotech, INC. | $791.77 | 2019-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $566.20 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $363.29 | 2023-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $333.30 | 2023-2025 | Dupixent |
| Pfizer INC. | $286.59 | 2021-2024 | |
| Leo Pharma INC. | $227.54 | 2019-2023 | Adbry |
| Strata Skin Sciences, INC. | $89.38 | 2021-2025 | Xtrac |
| Janssen Scientific Affairs, LLC | $82.55 | 2022 | |
| Dermavant Sciences, INC. | $78.60 | 2023-2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $54.77 | 2024-2025 | Zoryve |
| Lilly USA, LLC | $54.28 | 2021-2024 | Taltz, Ebglyss |
| Allergan, INC. | $50.40 | 2019-2020 | |
| Sun Pharmaceutical Industries INC. | $39.65 | 2021-2023 | Ilumya |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $33.87 | 2024-2025 | Nemluvio |
| Amgen INC. | $27.82 | 2022 | |
| Incyte Corporation | $27.26 | 2023 | Opzelura |
| Verrica Pharmaceuticals INC. | $24.13 | 2024 | Ycanth |
| Prugen, INC. Pharmaceuticals | $22.53 | 2020 | |
| Botanix Sb INC | $16.92 | 2025 | Sofdra |
| Ucb, INC. | $15.01 | 2024 | Bimzelx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramzi Saad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.